1
|
Computer-Aided Drug Design Approaches to Study Key Therapeutic Targets in Alzheimer’s Disease. ACTA ACUST UNITED AC 2017. [DOI: 10.1007/978-1-4939-7404-7_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
2
|
Cheng H, Zhang R, Yang S, Wang M, Zeng X, Xie L, Xie C, Wu J, Zhong G. Assembly of Enantioenrichedcis-3a,8a-Hexahydropyrrolo[2,3-b]indole Scaffolds by Silver(I)-Catalyzed Asymmetric Domino Reaction of Isocyanoacetates in the Presence ofCinchona-Derived Chiral Phosphorus Ligands. Adv Synth Catal 2016. [DOI: 10.1002/adsc.201500538] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
3
|
Long J, Lee WS, Chough C, Bae IH, Kim BM. Synthesis toward CRHR1 Antagonists through 2,7-Dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one C–H Arylation. J Org Chem 2015; 80:4716-21. [DOI: 10.1021/jo502894r] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Jinghai Long
- Department
of Chemistry,
College of Natural Sciences, Seoul National University, Seoul 151-747, Republic of Korea
| | - Woong-Sup Lee
- Department
of Chemistry,
College of Natural Sciences, Seoul National University, Seoul 151-747, Republic of Korea
| | - Chieyeon Chough
- Department
of Chemistry,
College of Natural Sciences, Seoul National University, Seoul 151-747, Republic of Korea
| | - Il Hak Bae
- Department
of Chemistry,
College of Natural Sciences, Seoul National University, Seoul 151-747, Republic of Korea
| | - B. Moon Kim
- Department
of Chemistry,
College of Natural Sciences, Seoul National University, Seoul 151-747, Republic of Korea
| |
Collapse
|
4
|
Huang L, Cheng H, Zhang R, Wang M, Xie C. Exploring thein situUtilization of Cyclic Imine Intermediates Generated by Isocyanoacetate Cycloaddition: Convergent Assembly ofcis-3a,8a-Hexahydropyrrolo[2,3-b]indole Scaffolds. Adv Synth Catal 2014. [DOI: 10.1002/adsc.201400376] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
5
|
Barwell J, Gingell JJ, Watkins HA, Archbold JK, Poyner DR, Hay DL. Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs? Br J Pharmacol 2012; 166:51-65. [PMID: 21649645 DOI: 10.1111/j.1476-5381.2011.01525.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The calcitonin receptor (CTR) and calcitonin receptor-like receptor (CLR) are two of the 15 human family B (or Secretin-like) GPCRs. CTR and CLR are of considerable biological interest as their pharmacology is moulded by interactions with receptor activity-modifying proteins. They also have therapeutic relevance for many conditions, such as osteoporosis, diabetes, obesity, lymphatic insufficiency, migraine and cardiovascular disease. In light of recent advances in understanding ligand docking and receptor activation in both the family as a whole and in CLR and CTR specifically, this review reflects how applicable general family B GPCR themes are to these two idiosyncratic receptors. We review the main functional domains of the receptors; the N-terminal extracellular domain, the juxtamembrane domain and ligand interface, the transmembrane domain and the intracellular C-terminal domain. Structural and functional findings from the CLR and CTR along with other family B GPCRs are critically appraised to gain insight into how these domains may function. The ability for CTR and CLR to interact with receptor activity-modifying proteins adds another level of sophistication to these receptor systems but means careful consideration is needed when trying to apply generic GPCR principles. This review encapsulates current thinking in the realm of family B GPCR research by highlighting both conflicting and recurring themes and how such findings relate to two unusual but important receptors, CTR and CLR.
Collapse
Affiliation(s)
- James Barwell
- School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, UK
| | | | | | | | | | | |
Collapse
|
6
|
López-Vallejo F, Peppard TL, Medina-Franco JL, Martínez-Mayorga K. Computational methods for the discovery of mood disorder therapies. Expert Opin Drug Discov 2011; 6:1227-45. [PMID: 22647063 DOI: 10.1517/17460441.2011.637106] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Despite the significant progress, research is still needed to reveal details of the complex and dynamic chemical processes operating in the central nervous system (CNS) and their relationship to psychological effects such as mood disorders. The incidence of behavioral depression is widely spread worldwide, with an estimated 14.8 million adults diagnosed yearly in the United States alone. The efficacy of current antidepressants on 50 - 60% of patients, their slow onset of action and the prevalence of adverse side effects highlight the need for developing a new generation of improved antidepressants. Computational methods have the potential to aid in the discovery of mood modulators. AREAS COVERED This review contains three main sections: historical evolution of marketed antidepressants, physicochemical and structural properties of antidepressant compounds reported in the ChEMBL database and recent efforts in the design and discovery of antidepressants using computational methods. The authors provide details of the computational methods employed, from chemoinformatic analyses to molecular modeling. EXPERT OPINION While there have been numerous and important findings in depression research, the high cost and time spent on research into new therapies for brain disorders is a risky undertaking. Computational methodologies can be employed to speed up the discovery of new antidepressants and to detect new sources of chemical compounds with potential antidepressant activity. Compound collections containing compounds already approved in the pharmaceutical and food industries that cover the property space and complement the structural space of CNS drugs represent a promising starting point for the discovery of new antidepressant agents.
Collapse
|
7
|
Ribecai A, Bacchi S, Delpogetto M, Guelfi S, Manzo AM, Perboni A, Stabile P, Westerduin P, Hourdin M, Rossi S, Provera S, Turco L. Identification of a Manufacturing Route of Novel CRF-1 Antagonists Containing a 2,3-Dihydro-1H-pyrrolo[2,3-b]pyridine Moiety. Org Process Res Dev 2010. [DOI: 10.1021/op100147h] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Arianna Ribecai
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Sergio Bacchi
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Monica Delpogetto
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Simone Guelfi
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Angelo Maria Manzo
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Alcide Perboni
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Paolo Stabile
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Pieter Westerduin
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Marie Hourdin
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Sara Rossi
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Stefano Provera
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Lucilla Turco
- Chemical Development Department and Analytical Chemistry Department, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| |
Collapse
|
8
|
Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 2010; 15:371-83. [PMID: 20206287 DOI: 10.1016/j.drudis.2010.02.011] [Citation(s) in RCA: 129] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2009] [Revised: 12/16/2009] [Accepted: 02/24/2010] [Indexed: 01/02/2023]
Abstract
Corticotropin releasing factor (CRF) receptor antagonists have been sought since the stress-secreted peptide was isolated in 1981. Although evidence is mixed concerning the efficacy of CRF(1) antagonists as antidepressants, CRF(1) antagonists might be novel pharmacotherapies for anxiety and addiction. Progress in understanding the two-domain model of ligand-receptor interactions for CRF family receptors might yield chemically novel CRF(1) receptor antagonists, including peptide CRF(1) antagonists, antagonists with signal transduction selectivity and nonpeptide CRF(1) antagonists that act via the extracellular (rather than transmembrane) domains. Novel ligands that conform to the prevalent pharmacophore and exhibit drug-like pharmacokinetic properties have been identified. The therapeutic utility of CRF(1) antagonists should soon be clearer: several small molecules are currently in Phase II/III clinical trials for depression, anxiety and irritable bowel syndrome.
Collapse
|